Andrew D Zelenetz (Andrew Zelenetz)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 49

Top Topics

Chronic Lymphocytic Leukemia

Diffuse Large B Cell Lymphoma

Top Venues

Leukemia & lymphoma

Science (New York, N.Y.)

This page only lists publications with an associated author ORCID identifier.

Publications

Skye Montoya, Jessie Bourcier, Mark Noviski, Hao Lu, Meghan C Thompson, Alexandra Chirino, Thomas Jacob Jahn, Anya K Sondhi, Stefan Gajewski, Ying Siow May Tan, Stephanie Yung, Aleksandra Urban, Eric Wang, Cuijuan Han, Xiaoli Mi, Won Jun Kim, Quinlan L Sievers, Paul Auger, Hugo Bousquet, Nivetha Brathaban, Brandon Bravo, Melissa Gessner, Cristiana Guiducci, James N Iuliano, Tim Kane, Ratul Mukerji, Panga Jaipal Reddy, Janine Powers, Mateo Sanchez Garcia de Los Rios, Jordan Ye, Carla Barrientos Risso, Daniel Tsai, Gabriel Pardo, Ryan Q Notti, Alejandro Pardo, Maurizio Affer, Vindhya Nawaratne, Tulasigeri M Totiger, Camila Pena-Velasquez, Joanna M Rhodes, Andrew D Zelenetz, Alvaro Alencar, Lindsey Elizabeth Roeker, Sanjoy Mehta, Ralph Garippa, Adam J Linley, Rajesh Kumar Soni, Sigrid S Skånland, Robert J Brown, Anthony R Mato, Gwenn H Hansen, Omar Abdel-Wahab, Justin Taylor
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. Science (New York, N.Y.) 383 (6682) (2024)
Skye Montoya, Jessie Bourcier, Mark Noviski, Hao Lu, Meghan C Thompson, Alexandra Chirino, Thomas Jacob Jahn, Anya K Sondhi, Stefan Gajewski, Ying Siow May Tan, Stephanie Yung, Aleksandra Urban, Eric Wang, Cuijuan Han, Xiaoli Mi, Won Jun Kim, Quinlan L Sievers, Paul Auger, Hugo Bousquet, Nivetha Brathaban, Brandon Bravo, Melissa Gessner, Cristiana Guiducci, James N Iuliano, Tim Kane, Ratul Mukerji, Panga Jaipal Reddy, Janine Powers, Mateo Sanchez Garcia de Los Rios, Jordan Ye, Carla Barrientos Risso, Daniel Tsai, Gabriel Pardo, Ryan Q Notti, Alejandro Pardo, Maurizio Affer, Vindhya Nawaratne, Tulasigeri M Totiger, Camila Pena-Velasquez, Joanna M Rhodes, Andrew D Zelenetz, Alvaro Alencar, Lindsey Elizabeth Roeker, Sanjoy Mehta, Ralph Garippa, Adam J Linley, Rajesh Kumar Soni, Sigrid S Skånland, Robert J Brown, Anthony R Mato, Gwenn H Hansen, Omar Abdel-Wahab, Justin Taylor
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. Science (New York, N.Y.) 383 (6682) (2024)
Ashwath Gurumurthi, Kurt S Bantilan, Paul A Hamlin, Anita Kumar, Matthew J Matasar, Menglei Zhu, Ashlee Joseph, Ali Castro, Erin Biggar, Gilles Andre Salles, Andrew D Zelenetz, Gottfried von Keudell
A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma. Leukemia & lymphoma (2024)
Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji, Loretta J Nastoupil, Catherine Thieblemont, Renata Ursu, Nancy L Bartlett, Victoria R Nachar, Jonathan Weiss, Jane Osterson, Krish Patel, Joshua D Brody, Jeremy S Abramson, Matthew A Lunning, Nirav N Shah, Ayed Ayed, Manali Kamdar, Benjamin M Parsons, Paolo Caimi, Ian W Flinn, Alex F Herrera, Jeff P Sharman, Marshall McKenna, Philippe Armand, Brad S Kahl, Sonali M Smith, Andrew D Zelenetz, L Elizabeth Elizabeth Budde, Martin Hutchings, Tycel Jovelle Phillips, Michael J Dickinson
Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy. Blood (2024)
Skye Montoya, Jessie Bourcier, Mark Noviski, Hao Lu, Meghan C Thompson, Alexandra Chirino, Thomas Jacob Jahn, Anya K Sondhi, Stefan Gajewski, Ying Siow May Tan, Stephanie Yung, Aleksandra Urban, Eric Wang, Cuijuan Han, Xiaoli Mi, Won Jun Kim, Quinlan L Sievers, Paul Auger, Hugo Bousquet, Nivetha Brathaban, Brandon Bravo, Melissa Gessner, Cristiana Guiducci, James N Iuliano, Tim Kane, Ratul Mukerji, Panga Jaipal Reddy, Janine Powers, Mateo Sanchez Garcia de Los Rios, Jordan Ye, Carla Barrientos Risso, Daniel Tsai, Gabriel Pardo, Ryan Q Notti, Alejandro Pardo, Maurizio Affer, Vindhya Nawaratne, Tulasigeri M Totiger, Camila Pena-Velasquez, Joanna M Rhodes, Andrew D Zelenetz, Alvaro Alencar, Lindsey Elizabeth Roeker, Sanjoy Mehta, Ralph Garippa, Adam J Linley, Rajesh Kumar Soni, Sigrid S Skånland, Robert J Brown, Anthony R Mato, Gwenn H Hansen, Omar Abdel-Wahab, Justin Taylor
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. Science (New York, N.Y.) 383 (6682) (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, M Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared to R-CHOP. Blood advances (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, Maria Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood advances 8 (9) (2024)
Skye Montoya, Jessie Bourcier, Mark Noviski, Hao Lu, Meghan C Thompson, Alexandra Chirino, Thomas Jacob Jahn, Anya K Sondhi, Stefan Gajewski, Ying Siow May Tan, Stephanie Yung, Aleksandra Urban, Eric Wang, Cuijuan Han, Xiaoli Mi, Won Jun Kim, Quinlan L Sievers, Paul Auger, Hugo Bousquet, Nivetha Brathaban, Brandon Bravo, Melissa Gessner, Cristiana Guiducci, James N Iuliano, Tim Kane, Ratul Mukerji, Panga Jaipal Reddy, Janine Powers, Mateo Sanchez Garcia de Los Rios, Jordan Ye, Carla Barrientos Risso, Daniel Tsai, Gabriel Pardo, Ryan Q Notti, Alejandro Pardo, Maurizio Affer, Vindhya Nawaratne, Tulasigeri M Totiger, Camila Pena-Velasquez, Joanna M Rhodes, Andrew D Zelenetz, Alvaro Alencar, Lindsey Elizabeth Roeker, Sanjoy Mehta, Ralph Garippa, Adam J Linley, Rajesh Kumar Soni, Sigrid S Skånland, Robert J Brown, Anthony R Mato, Gwenn H Hansen, Omar Abdel-Wahab, Justin Taylor
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. Science (New York, N.Y.) 383 (6682) (2024)
Andrew D Zelenetz, Wojciech Jurczak, Vincent Ribrag, Kim Linton, Graham P Collins, Javier L Jiménez, Mark Bishton, Bhagirathbhai Dholaria, Andrea Mengarelli, Tycel J Phillips, Nagendraprasad Sungala, Gerardo Musuraca, Oonagh Sheehy, Eric Van Den Neste, Mitsuhiko Odera, Lu Miao, Daniel P Gold, Richard G Ghalie, Pier L Zinzani
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study. HemaSphere 8 (8) (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, Maria Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood advances 8 (9) (2024)
Skye Montoya, Jessie Bourcier, Mark Noviski, Hao Lu, Meghan C Thompson, Alexandra Chirino, Thomas Jacob Jahn, Anya K Sondhi, Stefan Gajewski, Ying Siow May Tan, Stephanie Yung, Aleksandra Urban, Eric Wang, Cuijuan Han, Xiaoli Mi, Won Jun Kim, Quinlan L Sievers, Paul Auger, Hugo Bousquet, Nivetha Brathaban, Brandon Bravo, Melissa Gessner, Cristiana Guiducci, James N Iuliano, Tim Kane, Ratul Mukerji, Panga Jaipal Reddy, Janine Powers, Mateo Sanchez Garcia de Los Rios, Jordan Ye, Carla Barrientos Risso, Daniel Tsai, Gabriel Pardo, Ryan Q Notti, Alejandro Pardo, Maurizio Affer, Vindhya Nawaratne, Tulasigeri M Totiger, Camila Pena-Velasquez, Joanna M Rhodes, Andrew D Zelenetz, Alvaro Alencar, Lindsey Elizabeth Roeker, Sanjoy Mehta, Ralph Garippa, Adam J Linley, Rajesh Kumar Soni, Sigrid S Skånland, Robert J Brown, Anthony R Mato, Gwenn H Hansen, Omar Abdel-Wahab, Justin Taylor
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. Science (New York, N.Y.) 383 (6682) (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, Maria Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood advances 8 (9) (2024)
Skye Montoya, Jessie Bourcier, Mark Noviski, Hao Lu, Meghan C Thompson, Alexandra Chirino, Thomas Jacob Jahn, Anya K Sondhi, Stefan Gajewski, Ying Siow May Tan, Stephanie Yung, Aleksandra Urban, Eric Wang, Cuijuan Han, Xiaoli Mi, Won Jun Kim, Quinlan L Sievers, Paul Auger, Hugo Bousquet, Nivetha Brathaban, Brandon Bravo, Melissa Gessner, Cristiana Guiducci, James N Iuliano, Tim Kane, Ratul Mukerji, Panga Jaipal Reddy, Janine Powers, Mateo Sanchez Garcia de Los Rios, Jordan Ye, Carla Barrientos Risso, Daniel Tsai, Gabriel Pardo, Ryan Q Notti, Alejandro Pardo, Maurizio Affer, Vindhya Nawaratne, Tulasigeri M Totiger, Camila Pena-Velasquez, Joanna M Rhodes, Andrew D Zelenetz, Alvaro Alencar, Lindsey Elizabeth Roeker, Sanjoy Mehta, Ralph Garippa, Adam J Linley, Rajesh Kumar Soni, Sigrid S Skånland, Robert J Brown, Anthony R Mato, Gwenn H Hansen, Omar Abdel-Wahab, Justin Taylor
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. Science (New York, N.Y.) 383 (6682) (2024)
Andrew D Zelenetz, Wojciech Jurczak, Vincent Ribrag, Kim Linton, Graham P Collins, Javier L Jiménez, Mark Bishton, Bhagirathbhai Dholaria, Andrea Mengarelli, Tycel J Phillips, Nagendraprasad Sungala, Gerardo Musuraca, Oonagh Sheehy, Eric Van Den Neste, Mitsuhiko Odera, Lu Miao, Daniel P Gold, Richard G Ghalie, Pier L Zinzani
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study. HemaSphere 8 (8) (2024)
Skye Montoya, Jessie Bourcier, Mark Noviski, Hao Lu, Meghan C Thompson, Alexandra Chirino, Thomas Jacob Jahn, Anya K Sondhi, Stefan Gajewski, Ying Siow May Tan, Stephanie Yung, Aleksandra Urban, Eric Wang, Cuijuan Han, Xiaoli Mi, Won Jun Kim, Quinlan L Sievers, Paul Auger, Hugo Bousquet, Nivetha Brathaban, Brandon Bravo, Melissa Gessner, Cristiana Guiducci, James N Iuliano, Tim Kane, Ratul Mukerji, Panga Jaipal Reddy, Janine Powers, Mateo Sanchez Garcia de Los Rios, Jordan Ye, Carla Barrientos Risso, Daniel Tsai, Gabriel Pardo, Ryan Q Notti, Alejandro Pardo, Maurizio Affer, Vindhya Nawaratne, Tulasigeri M Totiger, Camila Pena-Velasquez, Joanna M Rhodes, Andrew D Zelenetz, Alvaro Alencar, Lindsey Elizabeth Roeker, Sanjoy Mehta, Ralph Garippa, Adam J Linley, Rajesh Kumar Soni, Sigrid S Skånland, Robert J Brown, Anthony R Mato, Gwenn H Hansen, Omar Abdel-Wahab, Justin Taylor
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. Science (New York, N.Y.) 383 (6682) (2024)
Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji, Loretta J Nastoupil, Catherine Thieblemont, Renata Ursu, Nancy L Bartlett, Victoria Nachar, Jonathan Weiss, Jane Osterson, Krish Patel, Joshua D Brody, Jeremy S Abramson, Matthew A Lunning, Nirav N Shah, Ayed Ayed, Manali Kamdar, Benjamin Parsons, Paolo F Caimi, Ian W Flinn, Alex F Herrera, Jeffrey Sharman, Marshall McKenna, Philippe Armand, Brad S Kahl, Sonali M Smith, Andrew D Zelenetz, L Elizabeth Elizabeth Budde, Martin Hutchings, Tycel Jovelle Phillips, Michael J Dickinson
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood 143 (16) (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, Maria Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood advances 8 (9) (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, M Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared to R-CHOP. Blood advances (2024)
Skye Montoya, Jessie Bourcier, Mark Noviski, Hao Lu, Meghan C Thompson, Alexandra Chirino, Thomas Jacob Jahn, Anya K Sondhi, Stefan Gajewski, Ying Siow May Tan, Stephanie Yung, Aleksandra Urban, Eric Wang, Cuijuan Han, Xiaoli Mi, Won Jun Kim, Quinlan L Sievers, Paul Auger, Hugo Bousquet, Nivetha Brathaban, Brandon Bravo, Melissa Gessner, Cristiana Guiducci, James N Iuliano, Tim Kane, Ratul Mukerji, Panga Jaipal Reddy, Janine Powers, Mateo Sanchez Garcia de Los Rios, Jordan Ye, Carla Barrientos Risso, Daniel Tsai, Gabriel Pardo, Ryan Q Notti, Alejandro Pardo, Maurizio Affer, Vindhya Nawaratne, Tulasigeri M Totiger, Camila Pena-Velasquez, Joanna M Rhodes, Andrew D Zelenetz, Alvaro Alencar, Lindsey Elizabeth Roeker, Sanjoy Mehta, Ralph Garippa, Adam J Linley, Rajesh Kumar Soni, Sigrid S Skånland, Robert J Brown, Anthony R Mato, Gwenn H Hansen, Omar Abdel-Wahab, Justin Taylor
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127. Science (New York, N.Y.) 383 (6682) (2024)
Jennifer L Crombie, Tara Graff, Lorenzo Falchi, Yasmin H Karimi, Rajat Bannerji, Loretta J Nastoupil, Catherine Thieblemont, Renata Ursu, Nancy L Bartlett, Victoria R Nachar, Jonathan Weiss, Jane Osterson, Krish Patel, Joshua D Brody, Jeremy S Abramson, Matthew A Lunning, Nirav N Shah, Ayed Ayed, Manali Kamdar, Benjamin M Parsons, Paolo Caimi, Ian W Flinn, Alex F Herrera, Jeff P Sharman, Marshall McKenna, Philippe Armand, Brad S Kahl, Sonali M Smith, Andrew D Zelenetz, L Elizabeth Elizabeth Budde, Martin Hutchings, Tycel Jovelle Phillips, Michael J Dickinson
Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy. Blood (2024)
Kurt S Bantilan, Alexandra N Smith, Matthew John Maurer, Julie Teruya-Feldstein, Matthew J Matasar, Alison J Moskowitz, David J Straus, Ariela Noy, M Lia Palomba, Steven M Horwitz, Paul A Hamlin, Carol S Portlock, James R Cerhan, Thomas M Habermann, Gilles Andre Salles, Grzegorz S Nowakowski, Craig H Moskowitz, Andrew D Zelenetz
Matched control analysis suggests R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared to R-CHOP. Blood advances (2024)
Michael L Wang, Wojciech Jurczak, Pier Luigi Luigi Zinzani, Toby Andrew Eyre, Chan Yoon Y Cheah, Chaitra S Ujjani, Youngil Koh, Koji Izutsu, James N Gerson, Ian W Flinn, Benoît Tessoulin, Alvaro J Alencar, Shuo Ma, David John Lewis, Ewa Lech-Maranda, Joanna M Rhodes, Krish Patel, Kami Maddocks, Nicole Lamanna, Yucai Wang, Constantine S Tam, Tahla Munir, Hirokazu Nagai, Francisco Hernandez-Ilizaliturri, Anita Kumar, Timothy S Fenske, John Francis Seymour, Andrew D Zelenetz, Binoj Nair, Donald E Tsai, Minna Balbas, Richard A Walgren, Paolo Abada, Chunxiao Wang, Junjie Zhao, Anthony R Mato, Nirav N Shah
Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Mantle Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Efrat Luttwak, Mitchell R Smith, Andrew D Zelenetz
Is there a pathway for phosphatidylinositol 3-kinase delta inhibitors to be approved therapeutics for B-cell lymphoma therapy. Expert opinion on pharmacotherapy (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma 64 (3) (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma 64 (3) (2023)
Robert N Stuver, Esther Drill, David Qualls, Michelle Okwali, Connie Lee Batlevi, Philip C Caron, Ahmet Dogan, Zachary D Epstein-Peterson, Lorenzo Falchi, Paul A Hamlin, Steven M Horwitz, Brandon S Imber, Andrew M Intlekofer, William T Johnson, Niloufer Khan, Anita Kumar, Oscar B Lahoud, Jennifer Kimberly Lue, Matthew J Matasar, Alison J Moskowitz, Ariela Noy, Colette N Owens, M Lia Palomba, Heiko Schöder, Santosha A Vardhana, Joachim Yahalom, Andrew D Zelenetz, Gilles Andre Salles, David J Straus
Retrospective Characterization of Nodal Marginal Zone Lymphoma. Blood advances (2023)
William T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, Alison J Moskowitz, Robert N Stuver, Catherine R Maccaro, Natasha Galasso, Tiffany Chang, Niloufer Khan, Umut Aypar, Natasha E Lewis, Andrew D Zelenetz, M Lia Palomba, Matthew J Matasar, Ariela Noy, Audrey M Hamilton, Paul A Hamlin, Philip C Caron, David J Straus, Andrew M Intlekofer, Connie Lee Batlevi, Anita Kumar, Colette N Owens, Craig S Sauter, Lorenzo Falchi, Jennifer K Lue, Santosha A Vardhana, Gilles Andre Salles, Ahmet Dogan, Nikolaus D Schultz, Maria E Arcila, Steven M Horwitz
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy. Blood advances (2023)
David A Qualls, Ariela Noy, David J Straus, Matthew J Matasar, Craig H Moskowitz, Venkatraman Seshan, Ahmet Dogan, Gilles Andre Salles, Anas Younes, Andrew D Zelenetz, Connie Lee Batlevi
Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: an open label phase II study. Leukemia & lymphoma 64 (3) (2023)
Kurt S Bantilan, Neil E Kay, Sameer A Parikh, Kari G Rabe, Timothy G Call, Jose F Leis, Wei Ding, Susan L Slager, Jacob D Soumerai, Lindsey E Roeker, Anthony Mato, Andrew D Zelenetz
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & lymphoma 64 (2) (2022)
Laurence L de Leval, Ash A Alizadeh, Peter Leif Bergsagel, Elias Campo, Andrew John Davies, Ahmet Dogan, Jude Fitzgibbon, Steven M Horwitz, Ari M Melnick, William George Morice, Ryan D Morin, Bertrand Nadel, Stefano A Pileri, Richard Rosenquist, Davide Rossi, Itziar Salaverria, Christian Steidl, Steven P Treon, Andrew D Zelenetz, Ranjana H Advani, Carl E Allen, Stephen M Ansell, Wing C John Chan, James R Cook, Lucy B M Cook, Francesco d'Amore, Stefan Dirnhofer, Martin Dreyling, Kieron Dunleavy, Andrew L Feldman, Falko Fend, Philippe Gaulard, Paolo Ghia, John G Gribben, Olivier Hermine, Daniel James Hodson, Eric D Hsi, Giorgio Ga Inghirami, Elaine S Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfram Klapper, Won Seog Kim, Rebecca L King, Young-Hyeh Ko, Ann Steward LaCasce, Georg Lenz, José I Martin-Subero, Miguel Angel Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla-Fend, Scott J Rodig, Andreas Rosenwald, Gilles Andre Salles, Jesús San F Miguel, Kerry Joane Savage, Laurie Helen Sehn, Gianpietro C Semenzato, Louis M Staudt, Steven Howard Swerdlow, Constantine S Tam, Judith Trotman, Julie M Vose, Oliver Weigert, Wyndham H Wilson, Jane N Winter, Catherine J Wu, Pier Luigi Luigi Zinzani, Emanuele Zucca, Adam Bagg, David W Scott
Genomic profiling for clinical decision making in lymphoid neoplasms. Blood 140 (21) (2022)
Anita Kumar, Carla Casulo, Erel Joffe, Craig Moskowitz, John Gerecitano, Alison Moskowitz, Anas Younes, Pamela Drullinsky, Esther Drill, Morgan Choma, Clare Grieve, Ashlee Joseph, Leana Laraque, Dylan Schick, Andrew D Zelenetz, Paul Hamlin
Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design. Leukemia & lymphoma 63 (12) (2022)
Kurt S Bantilan, Neil E Kay, Sameer A Parikh, Kari G Rabe, Timothy G Call, Jose F Leis, Wei Ding, Susan L Slager, Jacob D Soumerai, Lindsey E Roeker, Anthony Mato, Andrew D Zelenetz
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & lymphoma 64 (2) (2022)
Kurt S Bantilan, Neil E Kay, Sameer A Parikh, Kari G Rabe, Timothy G Call, Jose F Leis, Wei Ding, Susan L Slager, Jacob D Soumerai, Lindsey E Roeker, Anthony Mato, Andrew D Zelenetz
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & lymphoma 64 (2) (2022)
Kurt S Bantilan, Neil E Kay, Sameer A Parikh, Kari G Rabe, Timothy G Call, Jose F Leis, Wei Ding, Susan L Slager, Jacob D Soumerai, Lindsey E Roeker, Anthony Mato, Andrew D Zelenetz
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & lymphoma 64 (2) (2022)
Jacob D Soumerai, Allison Rosenthal, Shannon K Harkins, Jessica Duffy, Carmen Mecca, Yingbing Wang, Ravinder K Grewal, Areej R El-Jawahri, Huiyun Liu, Cedric Menard, Ahmet Dogan, Lei Yang, Lisa M Rimsza, Kurt Bantilan, Haley Martin, Matthew M Lei, Sydney Mohr, Anna Kurilovich, Olga Mikhaylovna Plotnikova, Ekaterina Postovalova, Valentina Nardi, Jeremy S Abramson, Roberto Chiarle, Andrew D Zelenetz, Abner Louissaint
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. Blood 140 (16) (2022)
Lindsey Elizabeth Roeker, Tatyana A Feldman, Jacob D Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey, Andrew D Zelenetz, Lorenzo Falchi, Jae H Park, David J Straus, Camila Pena Velasquez, Sonia Lebowitz, Yehudit Fox, Kristen Battiato, Carissa Laudati, Meghan C Thompson, Elizabeth McCarthy, Sabrina Kdiry, Rosalba Martignetti, Teja Turpuseema, Michelle Purdom, Dana Paskalis, Hari P Miskin, Peter Sportelli, Lori A Leslie, Anthony R Mato
Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (18) (2022)
Thais Fischer, Andy Ni, Kurt S Bantilan, Jacob D Soumerai, Anna Alperovich, Connie Lee Batlevi, Anas Younes, Andrew D Zelenetz
The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma. Leukemia & lymphoma 63 (3) (2022)
Kurt S Bantilan, Neil E Kay, Sameer A Parikh, Kari G Rabe, Timothy G Call, Jose F Leis, Wei Ding, Susan L Slager, Jacob D Soumerai, Lindsey E Roeker, Anthony Mato, Andrew D Zelenetz
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & lymphoma (2022)
Kurt S Bantilan, Neil E Kay, Sameer A Parikh, Kari G Rabe, Timothy G Call, Jose F Leis, Wei Ding, Susan L Slager, Jacob D Soumerai, Lindsey E Roeker, Anthony Mato, Andrew D Zelenetz
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & lymphoma (2022)
Kurt S Bantilan, Neil E Kay, Sameer A Parikh, Kari G Rabe, Timothy G Call, Jose F Leis, Wei Ding, Susan L Slager, Jacob D Soumerai, Lindsey E Roeker, Anthony Mato, Andrew D Zelenetz
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & lymphoma 64 (2) (2022)
Elias Campo, Elaine S Jaffe, James R Cook, Leticia Quintanilla-Fend, Steven H Swerdlow, Kenneth C Anderson, Pierre Brousset, Lorenzo Cerroni, Laurence de Leval, Stefan Dirnhofer, Ahmet Dogan, Andrew L Feldman, Falko Fend, Jonathan W Friedberg, Philippe Gaulard, Paolo Ghia, Steven M Horwitz, Rebecca L King, Gilles Andre Salles, Jesús San F Miguel, John Francis Seymour, Steven P Treon, Julie M Vose, Emanuele Zucca, Ranjana Advani, Stephen Ansell, Wing-Yan Au, Carlos Barrionuevo, Peter Leif Bergsagel, Wing C Chan, Jeffrey I Cohen, Francesco d'Amore, Andrew John Davies, Brunangelo Falini, Irene M Ghobrial, Mariusz A Wasik, John G Gribben, Eric D Hsi, Brad S Kahl, Won-Seog Kim, Shaji K Kumar, Ann Steward LaCasce, Camille Laurent, Georg Lenz, John P Leonard, Michael P Link, Armando Lopez-Guillermo, Maria-Victoria Mateos-Manteca, Elizabeth A Macintyre, Ari M Melnick, Judith Trotman, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano A Pileri, Miguel Angel Piris, Barbara Pro, Vincent Rajkumar, Steven T Rosen, Birgitta Sander, Laurie Sehn, Margaret A Shipp, Sonali M Smith, Louis M Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H Wilson, Tadashi Yoshino, Pier Luigi Luigi Zinzani, Martin Dreyling, David W Scott, Jane N Winter, Andrew D Zelenetz
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 140 (11) (2022)
Meghan C Thompson, Rosemary A Harrup, Catherine C Coombs, Lindsey Elizabeth Roeker, Jeffrey J Pu, Michael Y Choi, Paul M Barr, John N Allan, Martin Simkovic, Lori Leslie, Joanna Rhodes, Elise A Chong, Manali Kamdar, Alan Skarbnik, Frederick Lansigan, Brittany McCall, Khalid Saja, Martin J S Dyer, Harriet Sarah Walter, Marcus Lefebure, Maria Thadani-Mulero, Michelle Boyer, Juliana Biondo, Kavita Sail, Beenish S Manzoor, Richard Furman, Kurt S Bantilan, Andre H Goy, Tatyana Feldman, Dominic LaBella, Stephen J Schuster, Jae Park, Lia Palomba, Andrew D Zelenetz, Toby Andrew Eyre, Arnon P Kater, John Francis Seymour, Anthony R Mato
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood advances 6 (15) (2022)
Oscar B Lahoud, Sean M Devlin, Molly A Maloy, Lindsey Elizabeth Roeker, Parastoo Bahrami Dahi, Doris M Ponce, Boglarka Gyurkocza, Guenther Koehne, James W Young, Hugo R Castro-Malaspina, Juliet N Barker, Esperanza B Papadopoulos, Ann A Jakubowski, Andrew D Zelenetz, Anthony R Mato, Sergio A Giralt, Miguel-Ángel Perales, Craig S Sauter
Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation. Blood advances 5 (14) (2021)
Alison J Moskowitz, Gunjan Shah, Heiko Schöder, Nivetha Ganesan, Esther Drill, Helen Hancock, Theresa Davey, Leslie Perez, Sunyoung Ryu, Samia Sohail, Alayna Santarosa, Natasha Galasso, Rachel Neuman, Brielle Liotta, William Blouin, Anita Kumar, Oscar B Lahoud, Connie Lee Batlevi, Paul Hamlin, David J Straus, Ildefonso Rodriguez-Rivera, Colette Owens, Philip Caron, Andrew M Intlekofer, Audrey Hamilton, Steven M Horwitz, Lorenzo Falchi, Erel Joffe, William T Johnson, Christina Lee, Maria Lia Palomba, Ariela Noy, Matthew J Matasar, Georgios Pongas, Gilles Andre Salles, Santosha A Vardhana, Beatriz Wills Sanin, Gottfried von Keudell, Joachim Yahalom, Ahmet Dogan, Andrew D Zelenetz, Craig H Moskowitz
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (28) (2021)
Brandon S Imber, Karen W Chau, Jasme Lee, Jisun Lee, Dana L Casey, Joanna C Yang, N Ari Wijentunga, Annemarie Shepherd, Carla Hajj, Shunan Qi, Monica R Chelius, Paul A Hamlin, M Lia Palomba, Erel Joffe, Zhigang Zhang, Andrew D Zelenetz, Gilles Andre Salles, Joachim Yahalom
Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients? Blood advances 5 (20) (2021)
Anita Kumar, Carla Casulo, Ranjana H Advani, Elizabeth Budde, Paul M Barr, Connie Lee Batlevi, Philip Caron, Louis S Constine, Savita V Dandapani, Esther Drill, Pamela Drullinsky, Jonathan W Friedberg, Clare Grieve, Audrey Hamilton, Paul A Hamlin, Richard T Hoppe, Steven M Horwitz, Ashlee Joseph, Niloufer Khan, Leana Laraque, Matthew J Matasar, Alison J Moskowitz, Ariela Noy, Maria Lia Palomba, Heiko Schöder, David J Straus, Shreya Vemuri, Joanna Yang, Anas Younes, Andrew D Zelenetz, Joachim Yahalom, Craig H Moskowitz
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (20) (2021)
Anthony R Mato, Lindsey E Roeker, Toby Andrew Eyre, Chadi Nabhan, Nicole Lamanna, Brian T Hill, Danielle M Brander, Paul M Barr, Frederick Lansigan, Bruce D Cheson, Arun K Singavi, Maryam Sarraf Yazdy, Nirav N Shah, John N Allan, Erica B Bhavsar, Joanna Rhodes, Kaitlin Kennard, Stephen J Schuster, AnnaLynn M Williams, Alan P Skarbnik, Andre H Goy, Julie M Goodfriend, Colleen Dorsey, Catherine C Coombs, Hande H Tuncer, Chaitra S Ujjani, Ryan Jacobs, Allison M Winter, John M Pagel, Neil Bailey, Anna Schuh, Mazyar Shadman, Andrea Sitlinger, Hanna Weissbrot, Sivraj Muralikrishnan, Andrew D Zelenetz, Amy A Kirkwood, Christopher Paul Fox
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Blood advances 3 (10) (2020)
Sven Borchmann, Erel Joffe, Craig H Moskowitz, Andrew D Zelenetz, Ariela Noy, Carol S Portlock, John F Gerecitano, Connie Lee Batlevi, Philip C Caron, Pamela Drullinsky, Audrey Hamilton, Paul A Hamlin, Steven M Horwitz, Anita Kumar, Matthew J Matasar, Alison J Moskowitz, Colette N Owens, Maria Lia Palomba, Anas Younes, David J Straus
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood 133 (20) (2019)